Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Overall MarketRank^™

1.69 out of 5 stars

Medical Sector

297th out of 2,043 stocks

Pharmaceutical Preparations Industry

125th out of 771 stocks

1.2 Analyst's Opinion

Consensus Rating
Alexion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 15 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $158.05, Alexion Pharmaceuticals has a forecasted downside of 7.0% from its current price of $169.91.
Amount of Analyst Coverage
Alexion Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

3.1 Community Rank

Outperform Votes
Alexion Pharmaceuticals has received 1,251 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Alexion Pharmaceuticals has received 774 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Alexion Pharmaceuticals has received 61.78% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALXN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Alexion Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Alexion Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alexion Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.03% of the stock of Alexion Pharmaceuticals is held by insiders.
Percentage Held by Institutions
87.27% of the stock of Alexion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Alexion Pharmaceuticals are expected to grow by 5.30% in the coming year, from $11.14 to $11.73 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alexion Pharmaceuticals is 39.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.87.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alexion Pharmaceuticals is 39.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 43.71.
Price to Earnings Growth Ratio
Alexion Pharmaceuticals has a PEG Ratio of 0.75. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Alexion Pharmaceuticals has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

Is Alexion Pharmaceuticals a buy right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 15 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Alexion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares.
View analyst ratings for Alexion Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Alexion Pharmaceuticals?

Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alexion Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Alexion Pharmaceuticals.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its earnings results on Thursday, April, 29th. The biopharmaceutical company reported $3.52 EPS for the quarter, beating analysts' consensus estimates of $3.16 by $0.36. The biopharmaceutical company earned $1.64 billion during the quarter, compared to analysts' expectations of $1.58 billion. Alexion Pharmaceuticals had a net margin of 16.32% and a trailing twelve-month return on equity of 23.16%. The business's quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned $3.22 EPS.
View Alexion Pharmaceuticals' earnings history.

How has Alexion Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALXN shares have increased by 102.8% and is now trading at $169.91.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ALXN?

21 equities research analysts have issued 12-month price targets for Alexion Pharmaceuticals' stock. Their forecasts range from $73.00 to $205.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $158.05 in the next twelve months. This suggests that the stock has a possible downside of 7.0%.
View analysts' price targets for Alexion Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:

Dr. Ludwig N. Hantson, CEO & Director (Age 58, Pay $4.25M) (LinkedIn Profile)
Dr. Aradhana Sarin M.D., Exec. VP & CFO (Age 46, Pay $1.75M) (LinkedIn Profile)
Mr. Brian M. Goff, Exec. VP and Chief Commercial & Global Operations Officer (Age 52, Pay $1.76M) (LinkedIn Profile)
Ms. Ellen V. Chiniara J.D., Esq., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 62, Pay $1.56M) (LinkedIn Profile)
Dr. John J. Orloff, Exec. VP and Head of R&D (Age 64, Pay $1.83M) (LinkedIn Profile)
Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
Mr. Christopher J. Stevo CFA, Head of Investor Relations
Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 49) (LinkedIn Profile)
Megan Goulart, Sr. Director of Corp. Communications
Ms. Becky Lillie, Interim Chief Human Experience Officer

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. Ludwig Hantson has an approval rating of 75% among Alexion Pharmaceuticals' employees.

Who are some of Alexion Pharmaceuticals' key competitors?

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of ALXN's competitors.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V).

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include LSV Asset Management (1.18%), The Manufacturers Life Insurance Company (0.64%), DnB Asset Management AS (0.45%), Sumitomo Mitsui Trust Holdings Inc. (0.32%), Scharf Investments LLC (0.25%) and Oak Ridge Investments LLC (0.15%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Tanisha Carino.
View institutional ownership trends for Alexion Pharmaceuticals.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , LSV Asset Management, Retirement Systems of Alabama, Envestnet Asset Management Inc., Strs Ohio, Virginia Retirement Systems ET AL, Empire Life Investments Inc., and PGGM Investments. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino.
View insider buying and selling activity for Alexion Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Oak Ridge Investments LLC, Picton Mahoney Asset Management, Samson Rock Capital LLP, Harvest Management LLC, Nisa Investment Advisors LLC, DekaBank Deutsche Girozentrale, and Havens Advisors LLC.
View insider buying and selling activity for Alexion Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $169.91.

How much money does Alexion Pharmaceuticals make?

Alexion Pharmaceuticals has a market capitalization of $37.55 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis.

How many employees does Alexion Pharmaceuticals have?

Alexion Pharmaceuticals employs 3,837 workers across the globe.

When was Alexion Pharmaceuticals founded?

Alexion Pharmaceuticals was founded in 1992.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

Where are Alexion Pharmaceuticals' headquarters?

Alexion Pharmaceuticals is headquartered at 121 SEAPORT BOULEVARD, BOSTON MA, 02210.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]

This page was last updated on 5/5/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Alexion Pharmaceuticals Stock Forecast, Price & News

Adding

Adding

Adding Alexion Pharmaceuticals, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links

Headlines

About Alexion Pharmaceuticals

MarketRank™

Overall MarketRank™